Solid Tumor, Adult Clinical Trial
Official title:
A Two-Part, Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of HTI-1066 in subjects with advanced solid tumors.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female =18 years of age 2. Subject must have an advanced solid tumor 3. ECOG Performance Status of 0 or 1 4. Life expectancy =12 weeks 5. Adequate laboratory parameters 6. Female subjects agree not to be pregnant or lactating from beginning of the study screening until 4 months after receiving the last treatment; Male and female subjects and their sexual partners are willing and able to employ a highly effective method of birth control/contraception. 7. Willing and able to comply with clinic visits and study-related procedures 8. Provide signed informed consent Exclusion Criteria: 1. Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products 2. Any concurrent therapy for cancer, radiation, or surgery within 4 weeks, except for minor palliative intent (this is to be discussed with sponsor) 3. Any concurrent use of anti-infective, anti-fungal, or anti-viral agent (exceptions are to be approved by the sponsor) 4. Any other prohibited or restricted medication as described in the study protocol. 5. Investigational therapy administered <5 half-lives before the first dose of HTI-1066 6. Any anticancer therapy administered <5 half-lives before first dose of HTI-1066; any prior immune-oncology products administered within 4 weeks or 5 half-lives before the first dose of HTI-1066 as described above; or surgery or radiotherapy administered within 4 weeks before the first dose of HTI-1066. 7. Active CNS metastases. 8. Cardiac disease (NYHA classes II-IV) including myocardial infarction within 6 months before enrollment, or unstable angina, congestive heart failure, or cardiac arrhythmia requiring treatment. 9. History or presence of an abnormal ECG, ECHO, or MUGA that is clinically meaningful. 10. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (e.g., hepatitis B or C) 11. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results 12. Active infection or an unexplained fever >38.5°C during Screening or on the first scheduled day of dosing. 13. Unresolved toxicities from previous anticancer therapy. |
Country | Name | City | State |
---|---|---|---|
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Sarah Cannon - Tennessee Oncology | Nashville | Tennessee |
United States | Honor Health Research Institute | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events | Number of participants with AEs and SAEs | Up to 2 year | |
Primary | Dose-limiting toxicity (DLT) | Number of participants with DLTs | Up to 2 years | |
Secondary | AUC | Area under the curve | Up to 1 year | |
Secondary | Cmax | Peak concentration at Tmax | Up to 1 year | |
Secondary | Anti-drug antibodies | Up to 2 year | ||
Secondary | Objective response rate | Up to 2 years | ||
Secondary | Progression-free survival (PFS) | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04551885 -
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT05054348 -
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088004 -
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Active, not recruiting |
NCT06026254 -
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
|
Phase 1 | |
Recruiting |
NCT06032845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
|
Phase 2 | |
Recruiting |
NCT06144671 -
GT201 Injection For The Treatment Of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Terminated |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
Recruiting |
NCT06075849 -
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
|
Phase 1 |